Which Companies Will Be Making the News in 2024?

Which companies will be making the news this year—from manufacturing expansions, to mergers & acquisitions, to other key strategic developments? Be among the newsmakers at The DCAT Member Company Announcement Forum at DCAT Week. Applications close Monday February 5.

Which companies will be making the news this year—from manufacturing expansions, to mergers & acquisitions, to other key strategic developments? Be among the newsmakers at The DCAT Member Company Announcement Forum at DCAT Week. Applications close Monday February 5.

Getting the latest news at DCAT Week
Kicking off DCAT Week, the flagship event of the Drug, Chemical & Associated Technologies Association (DCAT) and the premier industry event for companies engaged in bio/pharmaceutical development and manufacturing, the DCAT Member Company Announcement Forum is a much-anticipated program in which senior executives from DCAT Member Companies highlight major news from their companies most impactful to the global bio/pharmaceutical manufacturing value chain.

The program is where the industry gathers to hear about the latest manufacturing expansions across all segments: chemicals/chemical active pharmaceutical ingredient (API) manufacturing, biomanufacturing, drug-product manufacturing, and packaging. It is an opportunity to get the details on the capacity being added, when it is coming on line, and the levels of investment behind those expansions.

It is also where the industry comes to get an inside take on the latest in mergers and acquisitions (M&A) from the deal-makers themselves. Senior executives explain their companies’ strategic rationale behind their moves to build critical mass and the details behind those moves: updates on deal closure and post-M&A integration.  

The program is open to all DCAT Member Companies—bio/pharma companies, CDMOs/CMOs, and other suppliers—but companies must apply to be considered for a presentation slot for this prominent event and much sought-after podium time. 

Applications are closing Monday February 5, 2024. The DCAT Member Company Announcement Forum Oversight Committee will then select companies given podium time based on news priority and interest to DCAT Member Companies. A company’s news must be from 2024 and can involve a merger or acquisition, manufacturing expansion, or other major corporate strategic development. Content criteria and online applications can be found here.

Due to popular demand and the number of applications received, this year’s Forum has been expanded and will be held from 9:00 to 11:30 AM on Monday March 18, 2024. Companies of all sizes—large-, medium-, and small-sized companies—may apply to highlight announcements of importance to the industry. But presentation slots are limited, and applications must be received no later than Monday February 5, 2024.

Need examples of past announcements? Check out the companies that made the news at DCAT Week 2023.

Expect a full house and standing room only of DCAT Week’s influential attendees of senior to mid-level executives to be at the program. The DCAT Member Company Announcement Forum will be held at DCAT Week on Monday, March 18, 2024, from 9:00 to 11:30 AM, at the InterContinental Barclay, Grand Ballroom, in New York. Interested in attending? Click here for further information, including how to register to attend.    

Recent Feature Articles

Bio/Pharma’s Top 10: Biologic-Based Drugs

By
How do biologic-based drugs rank among leading products of the top bio/pharma companies? Which companies and products are leading the pack? DCAT Value Chain Insights takes an inside look.

Cancer Drugs: Market Outlook & Product Innovation

By
Global spending on oncology drugs, the industry’s largest therapeutic sector, is projected to reach $409 billion by 2028. What product innovation, trends, and commercialization strategies are at play?

Supplier Risk Management: The Double-Edged Sword

By
Mitigating supplier risk is imperative, but how can that goal be balanced with the challenges of supplier consolidation,  industry capacity limitations, internal constraints, and other uncertainty to assure supply? An upcoming DCAT webinar will provide a “buy-and-sell side” view on best practices and new insights on how to better assess and mitigate risk in sourcing and supplier selection and the initial make-versus-buy decision.

Manufacturing and Supply Lines: Cell & Gene Therapies

By
Although a niche market, cell and gene therapy development and manufacturing is an active area of investment by select bio/pharmaceutical majors, CDMOs/CMOs and smaller bio/pharmaceuticals. Which companies are expanding? DCAT Value Chain Insights rounds up the latest developments.